Mesoporous silica-coated silver nanoparticles as ciprofloxacin/siRNA carriers for accelerated infected wound healing

J Nanobiotechnology. 2022 Aug 23;20(1):386. doi: 10.1186/s12951-022-01600-9.

Abstract

The colonization of bacterial pathogens is a major concern in wound infection and becoming a public health issue. Herein, a core-shell structured Ag@MSN (silver core embedded with mesoporous silica, AM)-based nanoplatform was elaborately fabricated to co-load ciprofloxacin (CFL) and tumor necrosis factor-α (TNF-α) small interfering RNA (siTNF-α) (AMPC@siTNF-α) for treating the bacterial-infected wound. The growth of bacterial pathogens was mostly inhibited by released silver ions (Ag+) and CFL from AMPC@siTNF-α. Meanwhile, the loaded siTNF-α was internalized by macrophage cells, which silenced the expression of TNF-α (a pro-inflammatory cytokine) in macrophage cells and accelerated the wound healing process by reducing inflammation response. In the in vivo wound model, the Escherichia coli (E. coli)-infected wound in mice almost completely disappeared after treatment with AMPC@siTNF-α, and no suppuration symptom was observed during the course of the treatment. Importantly, this nanoplatform had negligible side effects both in vitro and in vivo. Taken together, this study strongly demonstrates the promising potential of AMPC@siTNF-α as a synergistic therapeutic agent for clinical wound infections.

Keywords: Antibacterial; Mesoporous silica; Skin infection; Synergistic therapy; Wound healing; siRNA.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Ciprofloxacin / pharmacology
  • Escherichia coli
  • Metal Nanoparticles*
  • Mice
  • RNA, Small Interfering / pharmacology
  • Silicon Dioxide / pharmacology
  • Silver / pharmacology
  • Tumor Necrosis Factor-alpha
  • Wound Healing
  • Wound Infection* / drug therapy

Substances

  • Anti-Bacterial Agents
  • RNA, Small Interfering
  • Tumor Necrosis Factor-alpha
  • Silver
  • Ciprofloxacin
  • Silicon Dioxide